Hindustan Unilever is set to acquire the remaining stake in plant-based nutrition brand OZiva in a deal reportedly worth $90 million, strengthening its position in women-focused wellness, protein and micronutrient products.
"The health and well-being segment presents significant headroom for growth, and we will strengthen our participation through OZiva" — Niranjan Gupta, Chief Financial Officer, HUL
Cedars-Sinai announced a $75 million research initiative led by the Barbra Streisand Women’s Heart Center to study cardiovascular aging in women, advancing long-term understanding of sex-specific heart health.
“Armed with this funding, we are eager to continue uncovering biological mechanisms behind sex-based differences in aging and heart health” — C.Noel Bairey Merz, Director, Barbra Streisand Women’s Heart Center
🔗 https://www.cedars-sinai.org/newsroom/barbra-streisand-womens-heart-center-leads-75m-aging-study/
INVO Fertility has completed the acquisition of an Indiana fertility clinic as part of its strategy to expand its clinical footprint and broaden access to fertility services.
"We are thrilled to complete the acquisition of Family Beginnings. This transaction not only expands our geographic footprint and enhances our portfolio of clinics, but it also advances our mission of increasing access to high-quality, patient-centered fertility care." — Steve Shum, CEO, INVO Fertility
UK diagnostics provider Medichecks has acquired My Menopause Centre, integrating menopause expertise with at-home hormone testing to strengthen its women’s health offering.
"This milestone reflects not only a strong product, but a remarkable team and community. I’m deeply proud of what we’ve built and excited to see My Menopause Centre grow further under Medichecks’ leadership.” — Helen Normoyle, Co-Founder and CEO, My Menopause Centre
Merck has received FDA approval for Keytruda in ovarian cancer, marking the immunotherapy’s first nod in this indication and expanding treatment options in gynaecologic oncology.
“These approvals mark an important moment for the ovarian cancer community, reflecting years of focused investment in Keytruda” — Gursel Aktan, VP of Clinical Development, Merck
Maven Clinic has partnered with Color to integrate oncofertility support into cancer care benefits, improving access to fertility preservation services for patients undergoing treatment.
“As cancer survival rates continue to improve, quality of life after treatment matters more than ever,” — Kate Ryder, Founder and CEO, Maven Clinic
UK-based Matresa has raised £315,000 to advance its maternal health platform focused on supporting women through pregnancy and postpartum care.
“Tailored care isn’t a privilege – it’s a right. Women and mothers deserve to feel safe and supported, and we need to do more to tackle this crisis.” — Mari-Carmen Sanchez-Morris, Founder, Matresa
Menopause advocacy brand GenM has expanded into Australia via a nationwide retail partnership with TerryWhite Chemmart, increasing access to menopause-friendly products.
“Entering the Australian market is a major milestone for GenM and powerful validation of the MTick® as a globally scalable and trusted retail category." — Heather Jackson, CEO & Co-Founder, GenM
Gedeon Richter has signed a development agreement for an antibody targeting endometriosis, strengthening its pipeline in women’s health therapeutics.
🔗 https://www.femtechworld.co.uk/entrepreneur/richter-signs-endometriosis-antibody-deal-ftsu26/
Agilent secured FDAclearance for its companion diagnostic test designed to support patientselection for Merck’s newly approved Keytruda indication.
